Source MDx Announces Translational Molecular Medicine Collaboration With Pfizer Inc.

Published: Dec 27, 2007

BOULDER, CO--(Marketwire - December 27, 2007) - Source MDx, Inc. today announced a multi-year translational molecular medicine collaboration with Pfizer, Inc. to develop and validate RNA-based pharmacodynamic and predictive biomarkers within Pfizer's cancer and inflammation therapeutic development programs. This molecular diagnostics collaboration will combine Pfizer's expertise in genomic profiling with Source MDx's expertise in RNA transcription profiling to identify inflammation and cancer-related biomarkers in whole blood and circulating rare cells. Source MDx has developed and patented molecular diagnostic assays, Precision Profiles™, for over 1,800 target genes based on RNA transcript measurement using quantitative RT-PCR optimized for precision and calibration. Pfizer and Source MDx researchers will seek to establish molecular profiles of response and resistance for critical cancer and inflammation drugs. Validation of candidate biomarkers will lead to joint commercial opportunities in companion diagnostics.

Back to news